Glaxo Makes $5.1B Move Into Cancer Drugs
The acquisition of Tesaro fits Glaxo's focus on gene-based therapies but investors are concerned it is paying too steep a price.
CFOs on the Move: Week Ending Aug. 10
Travelers, GlaxoSmithKline, Blue Shield of Calif., Crocs, LLOG Exploration, Fry Communications, Russell Reynolds, Netgear, XPO Logistics, FactSet Research
GSK Buys Novartis out of Joint Venture for $13B
The acquisition of Novartis' stake will give GSK full control over the revenues from such products as Sensodyne toothpaste and the Excedrin pain reliever.
Why SMB CFOs Should Care About Transfer Pricing
Small and mid-tier manufacturers incorrectly assume that because they’re small, their transfer-pricing policy won’t be audited. They're wrong.